Press Releases

Publications

News Articles

Media Kit

Scipher Medicine Signs Multi-Target Partnership with Ionis

Scipher Medicine Signs Multi-Target Partnership with Ionis

Focus on development of precision therapeutics could lead to new and more effective treatments in disease areas including cardiovascular and CNS WALTHAM, Mass.--(July 17, 2023, BUSINESS WIRE)--Scipher Medicine today announced that it has entered into a multi-disease...

Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)

Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)

Jeffrey Curtis1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1University of Alabama at Birmingham, Hoover, AL, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA...

Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis

Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis

 Johanna Withers, PhD; Lixia Zhang, PhD; Sam Asgarian, MD Presented at EULAR 2022 Copenhagen, Denmark - June 1-4, 2022 Background: Despite drug therapies that improve lives, tens of millions of patients annually are subjected to therapy using a “trial-and-error”...

Can a Blood-Based Test Predict TNFi Nonresponse in RA?

Can a Blood-Based Test Predict TNFi Nonresponse in RA?

Richard Mark Kirkner via Medscape A blood test that uses a patient’s unique genetic signature has shown some ability to predict nonresponse to tumor necrosis factor inhibitors as treatment for rheumatoid arthritis, an observational clinical study has found, but...

Pandemic versus pandemonium: fighting on two fronts

Pandemic versus pandemonium: fighting on two fronts

The Lancet The ongoing COVID-19 pandemic has motivated many across the globe to adopt different approaches to understand the virus, surveil how the virus spreads, and search for effective treatments. This health crisis has focused global efforts on leveraging...

COVID-19 might be bitter medicine for what ails AI investing

COVID-19 might be bitter medicine for what ails AI investing

Silicon AngleR. Danes Is investor belt-tightening brought on by COVID-19 the bitter medicine needed to bring sanity to the artificial intelligence funding bubble, flush out fakes, and shift venture capitalists’ attention to the most deserving companies? In...

Coronavirus: AI steps up in battle against Covid-19

Coronavirus: AI steps up in battle against Covid-19

BBCJane Wakefield, Technology Reporter Normally, just getting them all to work together would take "a year of paperwork", said Scipher's chief executive Alif Saleh. But a series of Zoom calls with a "group of people with a unprecedented determination to get things...